Safety and Efficacy of KER-065 in Participants With Duchenne Muscular Dystrophy
Study sponsor: Keros Therapeutics, Inc. · KROS
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2028-08-26Estimated
Enrollment · participants36Estimated
Source updated2026-11-13Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.